Stories about: Norwood
- +
Virosome studied by MedImmune 18/07/2008 11:12:41
Norwood Abbey subsidiary's technology to be evaluated by MedImmune - +
Stem cells, tolerance and rebooting the thymus 15/06/2007 11:56:56
Question time with Professor Richard Boyd. - +
Norwood Immunology begins phase II of cancer trial 22/02/2006 14:19:04
The first of 80 patients have been enrolled in Norwood Immunology's (AIM:NIM) phase II clinical trial using its thymus-rejuvenating technology in cancer patients receiving self-derived (autologous) bone marrow transplants. - +
In brief: Narhex, Norwood Abbey, Anadis, Phylogica 02/02/2006 14:19:42
Narhex Life Sciences (ASX:NLS) has signed a manufacturing contract with Indian, Nasdaq-listed company Dr Reddy's for initial GMP-grade production of the prodrug of Narhex's candidate HIV protease inhibitor, DG35. - +
Norwood in Greek eyecare partnership 01/02/2006 13:15:47
Norwood Abbey's (ASX:NAL) Norwood Eyecare division is to partner with the University of Crete, in Greece, on R&D in the field of Epi-LASIK refractive surgery and related innovations. - +
Norwood Abbey to test virosomal delivery 27/01/2006 13:15:49
Norwood Abbey (ASX:NAL) has initiated animal studies for the use of its needle-free injection device for delivering virosomes, potent carriers of antigens for vaccination. - +
Norwood in bid to buy Dutch vaccine firm 19/01/2006 14:20:49
Immune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has entered into an option to acquire all the share capital of Netherlands-based Bestewil Holding, the 100 per cent owner of Virosome Biologicals Group, for up to 25 million euros (AUD$40.5 million). - +
Norwood commences phase II cancer vaccine trial 21/11/2005 14:51:23
Melbourne meditech Norwood Immunology (AIM:NIM) has recruited the first of 100 post-surgical melanoma patients into a phase II clinical trial of its thymus-rejuvenating technology, using the gonadotrophin releasing hormone (GNRH) analogue Lupron Depot. - +
Positive performance for Australian life sciences sector 16/11/2005 15:28:36
The Australian life sciences sector has picked up with small cap stocks seeing positive growth in the last quarter, according to the November edition of PricewaterhouseCoopers' quarterly BioForum report. - +
Norwood Immunology to seek IPO in US 15/11/2005 13:53:37
Immune therapy developer and Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology (AIM:NIM) has revealed plans to seek an initial public offering (IPO) in the USA, subject to market conditions. - +
Epitan files patent, Norwood Abbey granted patent 24/10/2005 15:05:29
Melbourne-based Epitan (ASX:APT, ADR:EPTNY, XETRA:UR9) has filed for a full international patent to protect the commercial use of the topical formulation of its melanin producing drug EPT1647 (formerly Melanotan).
Additional Resources
Newsletter Subscription
Australian Life Scientist Member Login
IDC Says Asia/Pacific Excluding Japan IT Market Will Remain The Bright Spot... 2008-12-04 15:04:00+11
AOC Launches 18.5” Widescreen Green 16:9 LCD Monitor in Australia and New Zealand 2008-12-03 15:30:00+11
“Just Graphics” isn’t enough any more 2008-11-28 15:02:00+11
Capture and Digitize Your Treasure Moments ~ Compro VideoMate C200 USB A/V Capture Stick 2008-11-26 12:37:00+11
AOC's Widescreen 22" LCD Monitor with All-Aluminum Chassis: Zifas 2218Ph - Flexible flair for discerning users 2008-11-24 13:30:00+11
Sponsored Links


